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Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-
hospital morbidity and mortality. A majority of these VTE events occur post-discharge,
and patients remain at increased VTE risk for up to 3months post-discharge. Recent
clinical trials of extended-duration thromboprophylaxis with enoxaparin, rivaroxaban,
and apixaban in acute medically ill patients did not demonstrate a net clinical benefit
compared with in-hospital thromboprophylaxis, and were shown to be associated with
higher risks of major bleeding. Betrixaban is a new direct oral anticoagulant (DOAC)
with a different pharmacokinetic profile than other DOACs. Betrixaban has the longest
half-life among the DOAC class, with a terminal half-life of 35–45 h and an effective
half-life of 19–27 h. Betrixaban has a low peak-to-trough ratio compared with other
anticoagulants and a predictable duration of drug exposure, leading to overall consis-
tent anticoagulant effect over 24h. Betrixaban is mainly cleared via the hepatobiliary
system and therefore not contraindicated in patients with severe renal insufficiency.
Betrixaban was recently approved for the indication of extended thromboprophylaxis
in the United States based on the APEX trial of betrixaban 80mg once daily for 35–
42days compared with low molecular weight heparin enoxaparin for 106 4days in hos-
pitalized acute medically ill patients. This study demonstrated that extended-duration
betrixaban reduced VTE compared with standard-duration enoxaparin in acute medi-
cally ill patients, without increased risk of major bleeding. This patient population at
risk of VTE may benefit from extended prophylaxis, ensuring continuum of care from
in-hospital to post-discharge.
Introduction
Acute medically ill patients are at risk of venous throm-
boembolism (VTE), a leading potentially preventable cause
of in-hospital morbidity and mortality in Europe and the
United States (US).1–3 Patients remain at risk for up to
3months after hospital discharge, with the highest risk
period within the first 6weeks after discharge.4
Preventative measures to reduce the risk of VTE events
while hospitalized or after surgery include physical activity,
intermittent pneumatic compression, and prophylactic
doses of anticoagulants.2 Until 2017, parenteral
anticoagulants including low molecular weight heparins
(LMWH), unfractionated heparins, or fondaparinux for
106 4days were the only recommended drugs for throm-
boprophylaxis for acute medically ill patients.5 Notably, it
has been demonstrated in observational studies that in-
hospital prophylaxis alone does not protect patients against
post-discharge VTE events.6
Recent clinical trials have investigated whether acute
medically ill patients may benefit from extended-duration
thromboprophylaxis, i.e. 4 to 6weeks after discharge, with
the LMWH enoxaparin as well as rivaroxaban and apixa-
ban.7–9 In those trials, extended anticoagulant therapy was
not associated with a net clinical benefit compared with
standard-duration (106 4days) thromboprophylaxis
administered while hospitalized, and extended thrombo-
prophylaxis with enoxaparin, rivaroxaban, or apixaban was
associatedwith a higher risk of major bleeding.7–9
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Betrixaban is a direct oral anticoagulant (DOAC) that
directly inhibits factor Xa, with a different pharmacoki-
netic (PK) profile than other DOACs. The APEX study com-
pared betrixaban at a dose of 80mg once daily for 35 to
42days with the standard-duration LMWH enoxaparin (at a
dose of 40mg once daily) for 106 4days in hospitalized
acute medically ill patients.10 This study demonstrated
that extended prophylaxis with betrixaban led to a reduc-
tion in VTE compared with standard-duration enoxaparin,
without an increase in major bleeding. Clinical results for
betrixaban, including reduced rehospitalization rates,11
are reviewed in further detail in article 3 of this
supplement.12
Pharmacodynamics
Betrixaban competitively and reversibly inhibits free and
prothrombinase-bound factor Xa in a concentration-
dependent manner.9,13–15 It has a profound selectivity for
factor Xa above other serine proteases, including throm-
bin, and does not require a cofactor (such as anti-thrombin
III) for activity.13,16 In intrinsic and extrinsic coagulation
pathways, factor Xa plays a central role in the cascade of
blood coagulation for activation of prothrombin to throm-
bin (Figure 1).13 Direct-acting inhibitors of factor Xa
decrease thrombin generation, and thereby prevent clot
formation.13
Pharmacokinetics
The pharmacology of betrixaban is distinct from that of
other DOACs, including the lowest renal clearance and no
metabolism by CYP enzymes (Table 1). At a dose of 80mg,
betrixaban is rapidly absorbed, and its plasma concentra-
tion peaks after 3–4h. Bioavailability is 34% and is lowered
if taken with fatty food. Betrixaban is less protein-bound
(60%) than the other factor Xa inhibitors. Among DOACs,
betrixaban has the longest half-life (Table 1), with a
Figure 1 Coagulation cascade.17 XII, factor XII; XI, factor XI; IX, factor IX; VIII, factor VIII; VII, factor VII; Xa, factor Xa.
Table 1 Pharmacokinetic and pharmacodynamic properties of direct oral anticoagulants18,19
Betrixaban Apixaban Edoxaban Rivaroxaban Dabigatran
Target Factor Xa Factor Xa Factor Xa Factor Xa Thrombin
Half-life (h) 19–27 12 10–14 5–9 12–17
Dosing o.d. b.i.d. o.d. o.d. (b.i.d.) b.i.d.
Tmax (h) 3–4 1–3 1–2 2–4 2
Bioavailability (%) 34 50 62 66 7
Renal excretion (%) 17.8a 25 35 66 >80
Faecal excretion (%) 85b 46.7–56 62.2 26.4 82–88
CYP450 metabolism No Yes No Yes No
b.i.d., twice daily; o.d., once daily; Tmax: time to reach peak concentration in plasma after oral dose.
aUnchanged betrixaban in urine following an intravenous betrixaban dose.
bFollowing oral administration of radio-labelled betrixaban.
Pharmacological properties of betrixaban E13
terminal half-life of 35 to 45h and an effective half-life of
19 to 27h.18 Betrixaban has a low peak-to-trough ratio and
a predictable duration of drug exposure, leading to an
overall consistent anticoagulant effect over 24h.18 For the
80-mg betrixaban doses, the anticipated Cmax is 36ng/mL,
and the volume of distribution is 32 L/kg. Betrixaban has
slightly non-linear kinetics, which show that increasing
doses are associated with greater than proportional
increases in plasma concentrations.
Unlike apixaban and rivaroxaban, betrixaban is not
metabolized by CYP enzymes (<1%) and does not induce or
inhibit cytochrome P450 (CYP450) activity, lowering
the risk of adverse drug events or interactions during
concomitant administration.18 Drugs that alter or compete
for CYP enzyme activity can change the PK of concurrent
medications that are metabolized by CYP450 enzymes,
including antibiotics (e.g. ciprofloxacin, metronidazole,
trimethoprim/sulfamethoxazole, clarithromycin, erythro-
mycin), antifungals (e.g. ketoconazole, nefazodone, itraco-
nazole, fluconazole), anticonvulsants (i.e. carbamazepine,
phenytoin, phenobarbital), and antihypertensives (e.g.
verapamil, diltiazem), drugs that are often administered to
acute medically ill patients.20 In contrast, betrixaban is a
substrate of P-glycoprotein.18 Dedicated Phase 1 studies
found elevated betrixaban exposure when coadministered
with the strong P-glycoprotein inhibitors, such as ketocona-
zole.19 A PK analysis of the population from the APEX study
also confirmed that P-glycoprotein inhibitors increase
betrixaban concentrations when coadministered, and a
dose reduction to 40mg is appropriate.21
A proportion of patients at risk for VTE have renal or hep-
atic insufficiency.22 Betrixaban is primarily excreted in the
gut (85%) through bile via the hepatobiliary system, as well
as via the P-glycoprotein efflux pump, mostly unmetabol-
ized.18,19 Patients with hepatic impairment [defined as cir-
rhosis, bilirubin >2 upper limit of normal (ULN), or liver
enzymes >3 ULN] should not receive betrixaban, and
obstructive jaundice could also cause drug accumulation.18
The low renal clearance of betrixaban (11% following oral
administration of radio-labelled betrixaban; 17.8% of the
absorbed dose was observed as unchanged betrixaban in
urine following intravenous administration); however, cre-
ates the possibility of safe administration in patients with
severe renal impairment, defined as a reduced glomerular
filtration with creatinine clearance 15 to <30mL/min.19
Patients with severe renal insufficiency had higher plasma
concentrations of betrixaban after full (80mg) and half
(40mg) doses compared with patients with normal kidney
function in the pivotal APEX trial.23 However, increases in
plasma concentration in this patient population were not
associated with an increase in major bleeding at the 80mg
or 40mg dose of betrixaban.19,23 Therefore, the betrixaban
label in the US supports use of betrixaban in patients with
severe renal impairment (in contrast with other DOACs),
but because these patients are still at increased risk of
bleeding events, betrixaban dosage should be reduced to
40mg.19 Even so, decisions on initiation and type of throm-
boprophylaxis in acute medically ill patients with severe
renal insufficiency need to be individually tailored.
Conclusion
Betrixaban, approved in the US for extended thrombopro-
phylaxis in hospitalized acute medically ill patients at risk
of VTE, is a new direct factor Xa inhibitor with pharmaco-
logical properties that make it particularly appropriate for
the acute medically ill population: a long half-life, a low
peak-to-trough concentration ratio, low renal clearance,
and no metabolism by CYP enzymes. These properties have
several important clinical implications for the population
where adverse drug events due to renal impairment,
comorbidities, and polypharmacy are considerable.
Betrixaban has a consistent anticoagulant effect over 24h,
no contraindication in patients with severe renal insuffi-
ciency (dose reduction indicated), and a low propensity for
drug–drug interactions (dose reduction indicated for
patients on P-glycoprotein inhibitors).
Funding: Portola Pharmaceuticals, Inc., South San
Francisco, CA supported development of this supplement.
The authors wrote all drafts of the article and take respon-
sibility for its content.
Conflict of interest: F.A.K. reports research grants from Bayer,
research grants from Bristol-Myers Squibb, research grants from
Boehringer-Ingelheim, and non-financial research support from
Daiichi-Sankyo. M.V.H. reports independent research grants and
honoraria for consulting and giving presentations from Boehringer-
Ingelheim, Pfizer BMS, Aspen, Bayer Healthcare, Daiichi-Sankyo,
andMerck Sharp and Dohme (MSD).
References
1. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG,
Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E,
Samama MM, Spannagl M; VTE Impact Assessment Group in Europe
(VITAE). Venous thromboembolism (VTE) in Europe. The number of
VTE events and associated morbidity and mortality. Thromb
Haemost 2007;98:756–764.
2. Rathbun S. Cardiology patient pages. The Surgeon General’s call to
action to prevent deep vein thrombosis and pulmonary embolism.
Circulation 2009;119:e480–e482.
3. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de
Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC,
Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S,
Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino
ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR,
Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson
C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ,
Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart
Association Statistics Committee and Stroke Statistics
Subcommittee. Heart disease and stroke statistics-2017 UPDATE: a
report from the American Heart Association. Circulation 2017;135:
e146–e603.
4. Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S.
Duration of venous thromboembolism risk across a continuum in
medically ill hospitalized patients. J Hosp Med 2012;7:231–238.
5. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ,
Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of
VTE in nonsurgical patients: antithrombotic therapy and prevention
of thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest 2012;141:
e195S–e226S.
6. Mahan CE, Fisher MD, Mills RM, Fields LE, Stephenson JJ, Fu AC,
Spyropoulos AC. Thromboprophylaxis patterns, risk factors, and out-
comes of care in the medically ill patient population. Thromb Res
2013;132:520–526.
E14 M.V. Huisman and F.A. Klok
7. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P,
Vicaut E, Turpie AG, Yusen RD; EXCLAIM study. Extended-duration
venous thromboembolism prophylaxis in acutely ill medical patients
with recently reduced mobility: a randomized trial. Ann Intern Med
2010;153:8–18.
8. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM,
Weitz JI; ADOPT Trial Investigators. Apixaban versus enoxaparin for
thromboprophylaxis in medically ill patients. N Engl J Med 2011;
365:2167–2177.
9. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A,
Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN
Investigators. Rivaroxaban for thromboprophylaxis in acutely ill
medical patients. N Engl J Med 2013;368:513–523.
10. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A,
Hernandez AF, Gibson CM; APEX Investigators. Extended thrombopro-
phylaxis with betrixaban in acutely ill medical patients. N Engl J
Med 2016;375:534–544.
11. Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen
AT, Harrington RA, Gibson CM. Extended-duration betrixaban reduces
the risk of rehospitalization associated with venous thromboembolism
among acutely ill hospitalized medical patients: findings from the
APEX trial (Acute Medically Ill Venous Thromboembolism Prevention
With Extended Duration Betrixaban Trial). Circulation 2018;137:91–94.
12. Beyer-Westendorf J, Verhamme P, Bauersachs P. Betrixaban for
prevention of venous thromboembolism in acute medically ill
patients. Eur Heart J Supp 2018; doi:10.1093/eurheartjsupp/suy017.
13. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez
AI, Vargas-Castrillon E, Rocha E. Potential role of new anticoagulants
for prevention and treatment of venous thromboembolism in cancer
patients. Vasc Health Risk Manag 2013;9:207–228.
14. Morganroth J, Gretler DD, Hollenbach SJ, Lambing JL, Sinha U.
Absence of QTc prolongation with betrixaban: a randomized, double-
blind, placebo- and positive-controlled thorough ECG study. Expert
Opin Pharmacother 2013;14:5–13.
15. Chan NC, Hirsh J, Ginsberg JS, Eikelboom JW. Betrixaban
(PRT054021): pharmacology, dose selection and clinical studies.
Future Cardiol 2014;10:43–52.
16. Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA,
Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong
PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G,
Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu
BY. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-
(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide,
a highly potent, selective, and orally efficacious factor Xa inhibitor.
Bioorg Med Chem Lett 2009;19:2179–2185.
17. Ansell J. Factor Xa or thrombin: is factor Xa a better target?
J Thromb Haemost 2007;5:60–64.
18. Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its
potential in the prevention and treatment of venous thromboembo-
lism. Vasc Health Risk Manag 2015;11:343–351.
19. Bevyxxa [package insert]. South San Francisco, CA: Portola
Pharmaceuticals Inc.; 2017.
20. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug
response, interactions, and adverse effects. Am Fam Physician 2007;
76:391–396.
21. Leeds JM, Wada DR, Bandman O, Gold A, Cohen AT, Curnutte JT,
Conley PB, Analysis of patient characteristics as covariates poten-
tially affecting pharmacokinetics, efficacy, or safety of betrixaban in
the APEX study. In: European Society of Cardiology. Barcelona,
Spain, 2017.
22. Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P,
Monreal M, Willich SN, Bramlage P, Agnelli G; PREFER in VTE
Scientific Steering Committee and the PREFER in VTE Investigators
(OBOT). The management of acute venous thromboembolism in clin-
ical practice. Results from the European PREFER in VTE Registry.
Thromb Haemost 2017;117:1326–1337.
23. Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK,
Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM,
Gold A, Harrington RA, Cohen AT; APEX Investigators. The safety and
efficacy of full- versus reduced-dose betrixaban in the Acute
Medically Ill VTE (Venous Thromboembolism) Prevention With
Extended-Duration Betrixaban (APEX) trial. Am Heart J 2017;185:
93–100.
Pharmacological properties of betrixaban E15
